



Do you have non-small cell lung cancer and have cancer cells remaining after your initial treatment and surgery?

If so, you may be eligible to participate in this study of a potential new treatment approach after surgery.


Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients with Non-Small Cell Lung Cancer

WHY consider participating in this study?

- Research studies are an important way to test the effectiveness of new therapies and approaches to treating cancer.
- The usual approach (i.e., the standard treatment most patients receive) for stage 2 to select stage 3B non-small cell lung cancer (NSCLC) that remains after initial treatment (chemo-immunotherapy and surgery) is additional immunotherapy, such as durvalumab.
 - Durvalumab is a drug that stimulates the immune system to attack cancer cells.
- The purpose of this study is to see if adding another drug called AZD6738 (ceralasertib) to the usual treatment can prolong the amount of time your non-small cell lung cancer takes to return.
 - AZD6738 (ceralasertib) is a drug that affects how cancer cells grow and divide. It is being studied in clinical trials, often in combination with other cancer treatments, to see how well it works and which patients may benefit most. In this study, it will be used in addition to durvalumab after surgery.

WHAT does this study involve?

- If you are eligible for EA5231/CLEAR and choose to participate, you may join the study at any point from the start of your initial treatment through the time you finish surgery.
- In order to participate, tests must show you have cancer cells remaining after surgery. You will be assigned by chance (randomized) to one of two study groups. Both groups will receive 12 cycles of treatment, and each cycle will be 4 weeks long. (A cycle refers to a period of treatment followed by a period of rest (no treatment) that is repeated on a regular schedule).
 - **Group 1 (about 315 people)** will receive durvalumab (the usual treatment for NSCLC after initial treatment and surgery).
 - » Durvalumab will be given through a vein in your arm (intravenously) on Day 1 of each cycle.
 - **Group 2 (about 315 people)** will receive ceralasertib in addition to durvalumab.
 - » Ceralasertib will be given as a pill you take by mouth on Days 1–7 of every cycle. Durvalumab will be given intravenously on Day 8 of each cycle.
 - » You will maintain a medication calendar to keep track of when you take ceralasertib at home. Your doctor will show you how to use this calendar. Each time you visit the clinic, you must bring the medication calendar, any remaining tablets, and the tablet bottle.
 - Cancer treatments can cause side effects. Your study doctor will review possible side effects with you, and you can ask questions about them at any time.



- For both groups, after you finish study treatment, your doctor will continue to monitor your condition for 10 years from when you enrolled in the study (every 3 months for the first 2 years, every 6 months for years 3–5, and then once per year for years 6–10).
 - » Some telemedicine visits are permitted, meaning you are not required to go into the clinic for every visit.

WHO will take part in this study?

- Approximately 630 people with NSCLC will take part in EA5231/CLEAR.
 - The cancer must be stage 2 to select stage 3B and must not have an *EGFR* or *ALK* mutation.
 - You must have completed at least 3 cycles of initial treatment (i.e. chemo-immunotherapy) before surgery.
- You can decide to stop taking part in this study at any time, for any reason, even after you have enrolled.

WHAT are the costs of taking part in this study?

- Just as if you were receiving the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you will receive as part of this study. This includes:
 - The costs of tests, exams, procedures, and medications that you get during the study to monitor your safety and prevent and treat side effects.
 - The costs of getting the durvalumab ready and giving it to you.
- You and/or your insurance provider will **not** have to pay for the durvalumab or AZD6738 (cerlasertib) while you take part in this study.
- Talk to your insurance provider to find out what they will pay for. If you are unsure which costs insurance will cover, ask your doctor or nurse for help finding the right person to talk to.
- Taking part in this study may mean that you need to make more visits to the clinic or hospital than if you were getting the usual approach to treat your cancer.
- You will not be paid for taking part in EA5231/CLEAR.

IF you would like more information:

- About the EA5231/CLEAR study, talk with your doctor, or:
 - Visit www.ecog-acrin.org and search EA5231, then select the link to the EA5231 page.
 - » If you are seeking information about the locations where this study is available, scroll down the page to Locations and Contacts and click the + sign.
 - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
- About clinical trials:
 - General cancer information: visit the NCI website at www.cancer.gov
 - Insurance coverage/paying for cancer treatment: www.cancer.gov/clinicaltrials/learningabout/payingfor
- About ECOG-ACRIN:
 - Visit www.ecog-acrin.org
 - For a list of patient resources and links to patient advocacy groups, visit www.ecog-acrin.org/patients/resources

